Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly

Share:
Related LLY
The Difference Between Shareholders And Stakeholders
Aside From The Recent Drug Failure, What Else Is Happening With Eli Lilly?
FDA OKs CV risk reduction claim for Lilly and BI's diabetes med Jardiance (Seeking Alpha)

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $46.00 to $52.00.

BofA Merrill Lynch noted, “Ramucirumab is a monoclonal antibody in development for multiple tumor types, with breast, lung and gastric being the furthest along in development (Phase III). Similar to Roche/Genentech's ~$6bn drug Avastin, ramu works by reducing tumors' access to blood supply. Ramu's specific mechanism of action is somewhat different, and based on pre-clinical and clinical data LLY believes that ramu could have some efficacy and/or tolerability advantages over Avastin. We are introducing preliminary sales estimates for ramu, with a launch in 2015 and sales ramping to a modest $500mn 5 years later.”

Eli Lilly & Co. closed on Tuesday at $44.71.

Latest Ratings for LLY

DateFirmActionFromTo
Nov 2016Atlantic EquitiesDowngradesOverweightNeutral
Nov 2016BMO CapitalDowngradesOutperformMarket Perform
Sep 2016Goldman SachsUpgradesNeutralBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!